References

1 www.abbottdiagnostics.com/About_Us/Hepatitis_Retrovirus/.

2 Ferguson, M., Heath, A. and Minor, P. D. Report of a study for assessing the potency of hepatitis vaccines. Biologicals 1990, 18, 345-350.

3 Wood, D. J., Heath, A. B. and Sawyer, L. A. A WHO collaborative study on assays of the antigenic content of inactivated poliovirus vaccines. Biologicals 1995, 23, 83-94.

4 Wood, D. J. and Heath, A. B. A WHO collaborative study of immunogeni-city assays of inactivated poliovirus vaccines. Biologicals 1995, 23, 301-311.

5 Mackett, M. Vaccinia virus vectors. In: Murray, J. A. H. (Ed.), Transgenesis: applications of gene transfer. John Wiley & Sons Ltd, Chichester, UK, 1992, pp. 155-186.

6 Moss, B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc. Natl. Acad. Sci. USA 1996, 93, 11341-11348.

7 Broeder, C. C. and Earl, P. L. Recombinant vaccinia viruses: Design, generation and isolation. Mol. Biotechnol. 1999, 13, 223-245.

8 Mastrangelo, M. J., Eisenlohr, L. C., Gomella, L. and Lattime, E. C. Poxvirus vectors: orphaned and underappreciated. J. Clin. Invest. 2000, 105, 1031-1034.

9 Paoletti, E., Taylor, J., Meignier, C., et al. Highly attenuated poxvirus vectors: NYVAC, ALVAC and TROVAC. Dev. Biol. Stand. 1995, 84, 159-163.

10 Pincus, S., Tartaglia, J. and Paoletti, E. Poxvirus-based vectors as vaccine candidates. Biologicals 1995, 23, 159-164.

11 Egan, M. A., Parlat, W. A. and Tartaglia, J. Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T-lymphocyte responses in seronegative adults by a non-replicating, host-range-restricted canary pox vector (ALVAC) carrying the HIV-1mn env gene. J. Dis. Infect. 1995, 171, 1623-1627.

12 Tine, J. A., Lanar, D. E., Smith, D., et al. NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. Infect. Immun. 1996, 64, 3833-3844.

13 Sutter, G. and Staib, C. Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery. Curr. Drug Targets Infect. Disord. 2003, 3, 263-271.

14 Marovich, M. A. ALVAC-HIV vaccines: clinical trial experience focusing on progress in vaccine development. Expert Rev. Vaccines 2004, 3 (Suppl. 4), S99-S104.

15 WHO informal consultation on characterization and quality aspect of vaccines based on live viral vectors. Meeting report, 2003. www.who.int/ vaccine_research/documents/vvreport/en/index11.html.

15 Connelly, S. Adenoviral vectors. In: Meager, A. (Ed.), Gene therapy technologies, applications and regulations: from laboratory to clinic. John Wiley & Sons Ltd, Chichester, UK, 1999, pp. 87-107.

16 Yeh, P. and Perricaudet, M. Advances in adenoviral vectors: from genetic engineering to their biology. FASEB J. 1997, 11, 615-623.

17 Lundstrom, K. Alphavirus-based vaccines. Curr. Opin. Mol. Ther. 2002, 4, 28-34.

18 Pushko, P., Parker, M., Ludwig, G. V., et al. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunisation against heterologous pathogens in vivo. Virology 1997, 239, 389-401.

19 Perri, S., Greer, C. E., Thudium, K., et al. An alphavirus replicon particle chimera derived from Venezuelan equine encephalitis and Sindbis viruses is a potent gene-base vaccine delivery system. J. Virol. 2003, 77, 9710-9715.

20 Davis, N. L., Caley, I. J., Brown, K. W., et al. Vaccination of macaques against a pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles. J. Virol. 2000, 74, 371-378.

21 Khatri, A., Xu, Z. Z. and Both, G. W. Gene expression by atypical recombinant ovine adenovirus vectors during abortive infection of human and animal cells in vitro. Virology 1997, 239, 226-237.

22 Slifka, M. K. and Ahmed, R. Long-lived plasma cells: a mechanism for maintaining persistent antibody production. Curr. Opin. Immunol. 1998, 10, 252-258.

24 Griffen, J. F. A strategic approach to vaccine development: animal models monitoring vaccine efficacy, formulation and delivery. Adv. Drug Deliv. Rev. 2002, 54, 851-861.

25 Moog, C., Fleury, H. J., Pelligrin, I., et al. Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type-1-infected individuals. J. Virol. 1997, 71, 3734-3741.

26 Richman, D. D., Wrin, T., Little, S. J. and Petropoulos, C. J. Rapid evolution of the neutralizing antibody response to HIV type infection. Proc. Natl. Acad. Sci. USA 2003, 100, 4144-4149.

27 Connor, R. I., Korber, B. T., Graham, B. S., et al. Immunological and viro-logical analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. J. Virol. 1998, 72, 1552-1576.

28 Pantophlet, R. and Burton, D. R. GP120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol. 2006, 24, 739-769.

29 Walker, B. D. and Korber, B. T. Immune control of HIV: the obstacles of HLA and viral diversity. Nat. Immunol. 2001, 2, 473-475.

30 Harrer, T., Harrer, E., Kalams, S. A., et al. Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable non-progressing HIV type 1 infection. AIDS Res. Hum. Retroviruses 1996, 12, 585-592.

31 Ogg, G. S., Xin, J., Bonhoeffer, S., et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma viral RNA load. Science 1998, 279, 2103-2106.

32 Betts, M. R., Ambrozak, D. R., Douek, D. C., et al. Analysis of total immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection. J. Virol. 2001, 75, 11983-11991.

33 Rosenberg, E. S., Billingsly, J. M., Caliendo, A. M., et al. Vigorous HIV-1-specific CD4+ T-cell responses associated with control of viraemia. Science 1997, 278, 1447-1450.

34 Rowland-Jones, S., Sutton, S. J., Ariyoshi, K., et al. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat. Med. 1995, 1, 59-64.

35 Rowland-Jones, S., Dong, T., Fowke, K. R., et al. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant seronegative prostitutes in Nairobi. J. Clin. Invest. 1998, 102, 1758-1765.

36 Pinto, L. A., Sullivan, J., Berkovsky, J. A., et al. ENV-specific cytotoxic T lymphocyte responses in HIV seronegative health-care workers occupationally exposed to HIV-contaminated body fluids. J. Clin. Invest. 1995, 96, 867-876.

37 Shearer, G. M. and Clerici, M. Protective immunity against HIV infection: Has nature done the experiment for us? Immunol. Today 1996, 17, 21-24.

38 Schmitz, J. E., Kuroda, M. J., Santra, S., et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 1999, 283, 857-860.

39 Kent, S. J., Woodward, A. and Zhao, A. Human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses correlate with the control of acute HIV-1 infection in macaques. J. Infect. Dis. 1997, 176, 1188-1197.

40 Matano, T., Shibata, R., Siemon, C., et al. Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/ human immunodeficiency virus during primary infections of macaques. J. Virol. 1998, 72, 164-169.

41 Jin, X., Bauer, D. E., Tuttleton, S. E., et al. Dramatic rise in plasma viremia after CD8+ T-cell depletion in simian immunodeficiency virus-infected macaques. J. Exp. Med. 1999, 189, 991-998.

42 Kaul, R., Rutherford, J., Rowland-Jones, S. L., et al. HIV-1 Env-specific cytotoxic T-lymphocyte responses in exposed, uninfected Kenyan sex workers: a prospective analysis. AIDS 2004, 18, 2087-2089.

43 Asquith, B., Edwards, C. T. T., Lipsitch, M., et al. Inefficient cytotoxic

T lymphocyte-mediated killing of HIV-1 infected cells in vivo. PLoS Biol. 2006, 4, e90.

44 Barouch, D. H., Santra, S., Schmitz, J. E., et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 2000, 290, 486-492.

45 Barouch, D. H., Craiu, A., Santra, S., et al. Elicitation of high frequency cytotoxic T-lymphocyte responses against both dominant and subdominant simian-human immunodeficiency virus epitopes by DNA vaccination of rhesus monkeys. J. Virol. 2001, 75, 2462-2467.

46 Barouch, D. H., Santra, S., Kuroda, M. J., et al. Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination. J. Virol. 2001, 75, 5151-5158.

47 Shiver, J. W., Fu, T. M., Chen, L., et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002, 415, 331-335.

48 Rose, N. F., Marx, P. A., Luckay, A., et al. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus. Cell 2001, 106, 539-549.

49 Horton, H., Vogel, T. U., Carter, D. K., et al. Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regime induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIV-mac239. J. Virol. 2002, 76, 7187-7202.

50 Pimsler, M. and Foreman, J. Estimates of the precursor frequency of cytotoxic T lymphocytes against antigens controlled by defined regions of the H-2 gene complex: comparison of the effect of H-2 differences due to intra-H-2 recombination vs. mutation. J. Immunol. 1978, 121, 1302-1305.

51 Murali-Krishna, M., Altman, J. D., Suresh, D. J. D., et al. Counting antigen-specific CD8+ T-cells: a re-evaluation of bystander activation during viral infection. Immunity 1998, 8, 177-188.

52 Butz, E. A. and Bevan, M. J. Massive expansion of antigen-specific CD8+ T-cells during an acute virus infection. Immunity 1998, 8, 167-176.

53 Busch, D. H., Pilip, I. M., Vijh, S. and Pamer, E. G. Coordinate regulation of complex T-cell populations responding to bacterial infection. Immunity 1998, 8, 353-362.

54 Czerkinsky, C., Nilsson, L-A., Tarkowski, A., et al. The solid phase enzyme-linked immunospot assay (ELISPOT) for enumerating antibody-secreting cells: Methodology and applications. In: Kemeny, D. M. (Ed.), ELISA and other solid phase immunoassays. John Wiley & Sons, Chichester, 1988, pp. 218-239.

55 Miyahara, Y., Murata, K., Rodriguez, D., et al. Quantification of antigen specific CD8+ T-cells using an ELISPOT assay. J. Immunol. Methods 1995, 181, 45-54.

56 Lalvani, A., Brookes, R., Hambleton, S., et al. Rapid effector function in CD8+ memory T-cells. J. Exp. Med. 1997, 186, 859-865.

57 Mwau, M., McMichael, A. J. and Hanke, T. Design and validation of an ELISPOT assay for use in clinical trials of candidate HIV vaccines. AIDS Res. Human Retroviruses 2002, 18, 611-618.

58 Coccia, E. M., Krust, B. and Hovanessian, A. G. Specific inhibition of viral protein synthesis in HIV-infected cells in response to interferon treatment. J. Biol. Chem. 1994, 269, 23087-23094.

59 Chichester, J. A., Feitelson, M. A. and Calkins, C. E. Different response requirements for IFNgamma production in ELISPOT assay by CD4+ T-cells from mice early and late after immunization. J. Immunol. Methods 2006, 309, 99-107.

60 Edwards, B. H., Bansal, A., Sabbaj, S., et al. Magnitude of functional CD8+ T-cell responses to the gag protein of human immunodeficiency virus type 1 correlates inversely with viral load in plasma. J. Virol. 2002, 76, 2298-2305.

61 Buseyne, F., Scott-Algara, D., Porrot, F., et al. Frequencies of ex vivo-activated human immunodeficiency virus type 1-specific y-interferon-producing CD8+ T-cells in infected children correlate positively with plasma viral load. J. Virol. 2002, 76, 12414-12422.

62 Trabattoni, D., Piconi, S., Biasin, M., et al. Granule-dependent mechanisms of lysis are defective in CD8 T-cells of HIV-infected, antiretroviral therapy-treated individuals. AIDS 2004, 18, 859-869.

63 Dalod, M., Dupuis, M., Deschemin, J. C., et al. Broad, intense antihuman immunodeficiency virus (HIV) ex vivo CD8+ responses in HIV type 1-infected patients: comparison with anti-Epstein-Barr virus responses and changes during antiretroviral therapy. J. Virol. 1999, 73, 7108-7116.

64 Addo, M. M., Yu, X. G., Rathod, A., et al. Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J. Virol. 2003, 77, 2081-2092.

65 Gea-Banacloche, J. C., Migueles, S. A., Martino, L., et al. Maintenance of large numbers of virus-specific CD8+ T-cells in HIV-infected progressors and long-term nonprogressors. J. Immunol. 2000, 165, 1082-1092.

66 Manz, R., Assenmacher, M., Pfluger, E., et al. Analysis and sorting of live cells to secreted molecules, relocated to a cell surface affinity matrix. Proc. Natl. Acad. Sci. USA 1995, 92, 1921-1925.

67 Picker, L. J., Singh, M. K., Zdraveski, Z., et al. Direct demonstration of cytokine synthesis heterogeneity among human memory/effector T-cells by flow cytometry. Blood 1995, 86, 1408-1419.

68 Sun, Y., Iglesias, E., Samri, A., et al. A systematic comparison of methods to measure HIV-1 specific CD8 T-cells. J. Immunol. Methods 2003, 272, 23-34.

69 Dunn, H. S., Haney, D. J., Ghanekar, S. A., et al. Dynamics of CD4 and CD8 T-cell responses to cytomegalovirus in healthy human donors.

70 Kagi, D., Lederman, B., Burki, K., et al. Cytotoxicity mediated by T-cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 1994, 369, 31-37.

71 Kagi, D., Seiler, P., Pavlovic, J., et al. The roles of perforin- and Fas-dependent cytotoxicity in protection against cytopathic and noncytopathic viruses. Eur. J. Immunol. 1995, 25, 3256-3262.

72 Topham, D. J., Tripp, R. A. and Doherty, P. C. CD8+ T-cells clear influenza virus by perforin- or Fas-dependent processes. J. Immunol. 1997, 159, 5197-5200.

73 Synder, J. E., Bowers, W. J., Livingstone, A. M., et al. Measuring the frequency of mouse and human cytotoxic T-cells by the Lysispot assay: independent regulation of cytokine secretion and short term killing. Nat. Med. 2003, 9, 231-235.

74 Masopust, D., Vezys, V., Marzo, A. L. and Lefrancois, L. Preferential localization of effector memory cells in lymphoid tissue. Science 2001, 291, 2413-2417.

75 Regner, M., Lobigs, M., Blanden, R. V. and Mullbacher, A. Effector cytolytic function but not IFN-y production in cytotoxic T-cells triggered by virus-infected target cell in vitro. Scand. J. Immunol. 2001, 54, 366-374.

76 Shankar, P., Russo, M., Harnisch, B., et al. Impaired function of circulating HIV-specific CD8+ T-cells in chronic human immunodeficiency virus infection. Blood 2000, 96, 3094-3101.

77 Trimble, L. A. and Lieberman, J. Circulating CD8 T lymphocytes in human immunodeficiency virus-infected individuals have impaired function and downmodulate CD3 the signaling chain of the T-cell receptor complex. Blood 1998, 91, 585-594.

78 Mueller, Y. M., Bojczuk, M., Halstead, E. S., et al. IL-15 enhances survival and function of HIV-specific CD8+ T-cells. Blood 2003, 101, 1024-1029.

79 Mueller, Y. M., DeRosa, S. C., Hutton, J. A., et al. Increased CD95/Fas-in-duced apoptosis of HIV-specific CD8+ T-cells. Immunity 2001, 15, 871-882.

80 Lichterfield, M., Yu, X. G., Waring, M. T., et al. HIV-1-specific cytotoxicity is preferentially mediated by a subset of CD8+ T-cells producing both interferon-y and tumour necrosis factor-a. Blood 2004, 104, 487-494.

81 Keoshkerian, E., Ashton, L. J., Smith, D. G., et al. Effective HIV-specific cytotoxic T-lymphocyte activity in long-term nonprogressors: associations with viral replication and progression. J. Med. Virol. 2003, 71, 483-491.

82 Appay, V., Nixon, D. F., Donahoe, S. M., et al. HIV-specific CD8+ T-cells produce antiviral cytokines but are impaired in cytolytic function.

83 Gray, C. M., Lawrence, J., Schapiro, J. M., et al. Frequency of class I HLA-restricted antiHIV CD8+ T-cells in individuals receiving highly active antiretroviral therapy (HAART). J. Immunol. 1999, 162, 1780-1786.

84 Synder-Cappione, J. E., Divekar, A. A., Maupin, G. M., et al. HIV-specific cytotoxic cell frequencies measured directly ex vivo by the Lysispot assay can be higher or lower than the frequencies of IFN-y-secreting cells: anti-HIV cytotoxicity is not generally impaired relative to other chronic virus responses. J. Immunol. 2006, 176, 2662-2668.

85 Brunner, K. T., Mauel, J., Cerotti, J. C. and Chapuis, B. Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro: inhibition by iso antibody and by drugs. Immunology 1968, 14, 181-186.

86 Lui, L., Chadroudi, A., Silvestri, G., et al. Visualization and quantification of T-cell mediated cytotoxicity using cell-permeable fluorogenic caspase substrates. Nat. Med. 2002, 8, 185-189.

87 Burkett, M. W., Shafer-Weaver, K. A., Strobl, S., et al. A novel flow cytometric assay for evaluating cell-mediated cytotoxicity. J. Immunother. 2005, 28, 396-402.

88 Devevre, E., Romero, P. and Mahnke, Y. D. LiveCount Assay: concomitant measurement of cytolytic and phenotypic characterisation of CD8(+) T-cells by flow cytometry. J. Immunol. Methods 2006,311, 31-46.

89 Edupuganti, S., Weber, D. and Poole, C. Cytotoxic T-lymphocyte responses to canarypox vector-based HIV vaccines in HIV-seronegative individuals: a meta-analysis of published studies. HIV Clin. Trials 2004, 5, 259-268.

90 Goepfert, P. A., Horton, H., McErath, M. J., et al. High dose Canarypox vaccine expressing HIV-1 protein, in seronegative human subjects.

91 Mwau, M., Cebere, I., Sutton, J., et al. A human immunodeficiency virus type 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J. Gen. Virol. 2004, 85, 911-919.

92 Estcourt, M. J., McMichael, A. J. and Hanke, T. DNA vaccines against human immunodeficiency virus type 1. Immunol. Rev. 2004, 199, 144-155.

93 Cebere, I., Dorell, L., McShane, H., et al. Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type I (HIV-1) vaccines administered alone and in prime-boost regime to healthy HIV-1 uninfected volunteers. Vaccine 2006, 24, 417-425.

94 Im, E. J. and Hanke, T. MVA as a vector for vaccines against HIV-1. Expert Rev. Vaccines 2004, 3 (Suppl 4), S89-S97.

95 Girard, M. P., Osmanov, S. K. and Kieny, M. P. A review of vaccine research and development: the human immunodeficiency virus (HIV). Vaccine 2006, 24, 4692-4700.

96 Santra, S., Seaman, M. S., Xu, L., et al. Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral responses in nonhuman primates. J. Virol. 2005, 79, 6516-6522.

97 Shiver, J. W., Fu, T. M., Chen, L., et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002, 415, 331-335.

98 Casimiro, D. R., Chen, L., Fu, T. M., et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J. Virol. 2003, 77, 6305-6313.

99 Shiver, J. W. and Emini, E. A. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu. Rev. Med. 2004, 55, 355-372.

100 Kotense, S., Koudstaal, W., Sprangers, M., et al. Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. AIDS 2004, 18, 1213-1216.

101 Barouch, D. H., Pau, M. G., Custers, J. H., et al. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J. Immunol. 2004, 172, 6290-6297.

102 Sauter, S. L., Rahman, A. and Muralidhar, G. Non-replicating viral vector-based AIDS vaccines: interplay between viral vectors and the immune system. Curr. HIV Res. 2005, 3, 157-181.

103 Rose, N. F., Marx, P. A., Luckay, A., et al. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 2001, 106, 539-549.

104 Publicover, J., Ramsburg, E. and Rose, J. K. A single-cycle vaccine vector based on vesicular stomatitis virus can induce immune responses comparable to those generated by a replication competent vector. J. Virol. 2005, 79, 13231-13238.

105 Schneider, J., Gilbert, S. C., Hannan, C. M., et al. Induction of CD8+ T-cells using heterologous prime-boost immunisation strategies. Immunol. Rev. 1999, 170, 29-38.

106 Schneider, J., Gilbert, S. C., Blanchard, T. J., et al. Enhanced immuno-genicity for CD8+ T-cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat. Med. 1998, 4, 397-402.

107 Anderson, R. J., Hannan, C. M., Gilbert, S. C., et al. Enhanced CD8+ T-cell immune responses and protection elicited against Plasmodium berghei malaria by prime boost immunization regimens using a novel attenuated fowlpox virus. J. Immunol. 2004, 172, 3094-3099.

108 Gilbet, S. C., Schneider, J., Hannan, C. M., et al. Enhanced CD8 T-cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunization regimes. Vaccine 2002, 20, 1039-1045.

109 Keating, S. M., Bejon, P., Berthoud, T., et al. Durable human memory T-cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria. J. Immunol. 2005, 175, 5675-5680.

110 Suematsu, S. and Watanabe, T. Generation of a synthetic lymphoid tissuelike organoid in mice. Nat. Biotechnol. 2004, 22, 1539-1545.

111 Poznansky, M. C., Evans, R. H., Foxall, R. B., et al. Efficient generation of human T-cells from a tissue-engineered thymic organoid. Nat. Biotechnol. 2000, 18, 714-715.

112 Trelease, R. B. and Park, J. Qualitative process modeling of cell-cell-pathogen interactions in the immune system. Comput. Methods Programs Biomed. 1996, 51, 171-181.

113 Ferrari, G., Humphrey, W., McElrath, M. J., et al. Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc. Natl. Acad. Sci. USA 1997, 94, 1396-1401.

114 Cao, H., Kaleebu, P., Hom, D., et al. Immunogenicity of a recombinant human immunodeficiency virus (HlV)-canarypox vaccine in HIV-seronegative Ugandan volunteers: results of the HIV Network for Prevention Trials 007 Vaccine Study. J. Dis. Infect. 2003, 187, 887-895.

115 Coupar, B. E., Purcell, D. F., Thomson, S. A., et al. Fowlpox virus vaccines for HIV and SHIV clinical and preclinical trials. Vaccine 2006, 24, 1378-1388.

116 Kelleher, A. D., Puls, R. L., Bebbington, M., et al. A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox boost prophylactic vaccine for HIV-1. AIDS 2006, 20, 294-297.

117 Mascola, J. R., Sambor, A., Beaudry, K., et al. Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins. J. Virol. 2005, 79, 771-779.

118 Spearman, P. Current progress in the development of HIV vaccines. Curr. Pharmaceut. Design 2006, 12, 1147-1167.

119 Casimiro, D. R., Bett, A. J., Fu, T. M., et al. Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors. J. Virol. 2004, 78, 11434-11438.

How To Bolster Your Immune System

How To Bolster Your Immune System

All Natural Immune Boosters Proven To Fight Infection, Disease And More. Discover A Natural, Safe Effective Way To Boost Your Immune System Using Ingredients From Your Kitchen Cupboard. The only common sense, no holds barred guide to hit the market today no gimmicks, no pills, just old fashioned common sense remedies to cure colds, influenza, viral infections and more.

Get My Free Audio Book


Post a comment